Intravenous Solutions Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 13.27 Billion |
| Market Size (2029) | USD 17.33 Billion |
| CAGR (2024 - 2029) | 5.49 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Intravenous Solutions Market Analysis
The Intravenous Solutions Market size is estimated at USD 13.27 billion in 2024, and is expected to reach USD 17.33 billion by 2029, at a CAGR of 5.49% during the forecast period (2024-2029).
The rising prevalence of chronic diseases, including gastrointestinal disorders, neurological conditions, and cancer, significantly propels intravenous solutions market growth as it plays a critical role in patient care. Cancer's impact on the body includes the depletion of vital resources, which alters metabolism and can lead to starvation and loss of lean body mass, ultimately resulting in malnutrition; this is particularly concerning given the rising incidence of the disease. For instance, according to a report published in the CA: Cancer Journal for Clinicians in January 2024, an estimated 2 million cancer cases are expected to be diagnosed in the United States in 2024. Thus, the anticipated increase in cancer diagnoses is driving demand for advanced therapeutic interventions, including intravenous solutions, as they play a critical role in the management and treatment of cancer-related symptoms and complications.
Moreover, the growing prevalence of pneumonia in recent years is also expected to boost the intravenous solutions market growth. For instance, according to a report published by the United Nations International Children's Emergency Fund in November 2023, globally, pneumonia affects over 1,400 children per 100,000 annually. The highest incidence rates are observed in South Asia, with 2,500 cases per 100,000 children, and in West and Central Africa, 1,620 cases per 100,000 children. Thus, the rising incidence of pneumonia, leading to increased hospitalizations and the need for intensive care treatments, drives the demand for intravenous solutions to support hydration, nutrition, and medication delivery in critical patient care.
Additionally, key players are implementing diverse growth strategies, including partnerships, to address the increasing demand for intravenous solutions. For instance, in October 2023, FranDevCo entered into a strategic partnership with IV Nutrition, a company specializing in intravenous hydration therapy. This collaboration aims to enhance wellness by providing essential nutrient therapies, reflecting the growing demand within the nutritional IVs market.
In conclusion, the rising prevalence of chronic diseases, including cancer and pneumonia, and advancements in intravenous solutions significantly drive the demand for specialized interventions in patient care, contributing to market growth.
However, regulatory and quality requirements are estimated to restrain the market growth.
Intravenous Solutions Market Trends
The Total Parenteral Nutrition Segment is Expected to Witness Significant Growth Over the Forecast Period
The high burden of gynecological cancer worldwide is driving demand for total parenteral nutrition (TPN) to deliver essential nutrition, while rising development efforts by market players are expanding TPN offerings to meet this growing need. For instance, according to a report published in the Bulletin du Cancer Journal in August 2023, the increasing prevalence of malnutrition in cancer patients, coupled with the need for more personalized and adequate nutritional support, has created a significant demand. This shift has led to a rise in the application of total parenteral nutrition (TPN). Additionally, the proactive implementation of quality control measures and more consistent adherence to best practices have improved the relevance and effectiveness of TPN in oncology care. These advancements are expected to propel the growth of the total parenteral nutrition segment.
Furthermore, according to a report published by the World Health Organization in March 2024, 390 million were underweight. Globally, an estimated 149 million children under five experienced impaired growth, and 45 million faced severe undernutrition. The high burden of malnourishment is projected to boost the demand for total parenteral nutrition to treat malnutrition, accelerating segment growth during the forecast period.
The rising approvals of innovative parenteral nutrition solutions for every age group are also expected to propel the segment’s growth during the forecast period. For instance, in March 2022, Fresenius Kabi was granted an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates. The fluid was approved as one of the first four oil lipid emulsions for parenteral nutrition patients of every age. It can be used in the hospital for home care settings.
In conclusion, the growing prevalence of malnutrition, particularly in cancer patients, coupled with the increasing approval of innovative parenteral nutrition solutions, is expected to drive significant growth in the total parenteral nutrition segment.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is anticipated to capture a substantial market share due to the ongoing product launches and regulatory approvals, and rising prevalence of cancer. For instance, according to a report published by the American Cancer Society in January 2024, the estimated number of urinary system cancers in the United States is over 169,360. The region’s high burden of these diseases is expected to create demand for intravenous solutions during hospitalization or at home, further boosting the market growth during the forecast period.
Furthermore, the high utilization of saline in the region is also expected to propel the growth of the intravenous solution market. For instance, according to a report published in the Heliyon Journal in September 2023, the increasing utilization of 0.9% sodium chloride intravenous fluid (normal saline) for hydration purposes has significantly contributed to the rising demand in healthcare settings, with over 200 million liters administered annually in the United States. This widespread use and life-saving capabilities ensure its continued presence as a key intravenous solution in patient care. As a result, the growing consumption of saline directly drives the expansion of the North America intravenous solution market.
Additionally, growth strategies adopted by the market players in the region significantly contribute to the market's growth. For instance, in May 2022, Fresenius Kabi acquired Ivenix, Inc., to expand its infusion therapies and intravenous fluids offering in the United States. Moreover, in February 2022, B. Braun Medical received the US FDA approval to begin operations at its new IV saline solution manufacturing facility in Daytona Beach, Florida.
In conclusion, the North America intravenous solution market is poised for significant growth due to ongoing strategic expansions by key market players, and increased demand for saline.
Intravenous Solutions Industry Overview
The intravenous solutions market is competitive due to the presence of companies operating internationally and regionally. These market participants are undertaking several organic and inorganic growth strategies to capture a higher revenue share in this industry. Some of the major players include Ajinomoto, B. Braun SE, Baxter International, Grifols, and ICU Medical Inc.
Intravenous Solutions Market Leaders
-
Ajinomoto
-
B. Braun SE
-
Baxter International
-
Grifols
-
ICU Medical Inc.
*Disclaimer: Major Players sorted in no particular order
Intravenous Solutions Market News
- October 2024: B. Braun Medical announced the plan to ramp up production of intravenous (IV) saline fluids by 20% at its plants in Irvine, California, and Daytona Beach, Florida.
- July 2024: Amneal Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for a new formulation of potassium phosphates in 0.9% sodium chloride injection, available in ready-to-use intravenous (IV) bags. This sterile presentation streamlines the administration process by minimizing the compounding steps typically clinicians require.
Intravenous Solutions Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Chronic Diseases
4.2.2 Rise in Adoption of IV Solutions Coupled with Surge in the Prevalence of Malnutrition
4.3 Market Restraints
4.3.1 Regulatory and Quality Requirements
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Total Parenteral Nutrition
5.1.2 Peripheral Parenteral Nutrition
5.2 By Solution Composition
5.2.1 Saline
5.2.2 Carbohydrates
5.2.3 Vitamins and Minerals
5.2.4 Other Solution Compositions
5.3 By End-User
5.3.1 Hospitals and Clinics
5.3.2 Ambulatory Centers
5.3.3 Homecare Settings
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Ajinomoto
6.1.2 B. Braun SE
6.1.3 Baxter International
6.1.4 Fresenius Kabi AG
6.1.5 Grifols
6.1.6 ICU Medical Inc.
6.1.7 Otsuka Pharmaceutical India Pvt. Ltd.
6.1.8 PHARMASYNTEZ
6.1.9 SGD Pharma
6.1.10 Vifor Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Intravenous Solutions Industry Segmentation
As per the report's scope, intravenous solutions are chemically prepared fluids administered in the body through venous circulation to maintain or replace the level of lost body fluid. The intravenous solutions market is segmented by type, solution composition, end-user, and geography. The type segment is further bifurcated into total and peripheral parenteral solutions. The solution composition is further divided into saline, carbohydrates, vitamins and minerals, and other solution compositions. The end-user segment is further segmented into hospitals and clinics, ambulatory centers, and home care settings. The geography segment is divided into North America, Europe, Asia-Pacific, Middle East, and Africa. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD for the above segments.
| By Type | |
| Total Parenteral Nutrition | |
| Peripheral Parenteral Nutrition |
| By Solution Composition | |
| Saline | |
| Carbohydrates | |
| Vitamins and Minerals | |
| Other Solution Compositions |
| By End-User | |
| Hospitals and Clinics | |
| Ambulatory Centers | |
| Homecare Settings |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Intravenous Solutions Market Research FAQs
How big is the Intravenous Solutions Market?
The Intravenous Solutions Market size is expected to reach USD 13.27 billion in 2024 and grow at a CAGR of 5.49% to reach USD 17.33 billion by 2029.
What is the current Intravenous Solutions Market size?
In 2024, the Intravenous Solutions Market size is expected to reach USD 13.27 billion.
Who are the key players in Intravenous Solutions Market?
Ajinomoto, B. Braun SE, Baxter International, Grifols and ICU Medical Inc. are the major companies operating in the Intravenous Solutions Market.
Which is the fastest growing region in Intravenous Solutions Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Intravenous Solutions Market?
In 2024, the North America accounts for the largest market share in Intravenous Solutions Market.
What years does this Intravenous Solutions Market cover, and what was the market size in 2023?
In 2023, the Intravenous Solutions Market size was estimated at USD 12.54 billion. The report covers the Intravenous Solutions Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Intravenous Solutions Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Intravenous Solutions Industry Report
Statistics for the 2024 Intravenous Solutions market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Intravenous Solutions analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
